EUCTR2012-005485-36-ES进行中（未招募）不适用
A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of Schizophrenia
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?The patient is able to read and understand the patient information sheet.
- •?Prior to any screening procedures, the patient must have signed the informed consent form.
- •?Men and women, aged between 18-65 years (extremes included), suffering from schizophrenia (DSM-IV-TR diagnosis, all subtypes allowed).
- •?The onset of schizophrenia has been known for at least 2 years prior to the Screening Visit.
- •?The patient should be known by the investigator, either directly or via another psychiatrist from the site or via a referring psychiatrist. Reliable source data including detailed history of the patient?s diagnosis of schizophrenia for at least a period of one year prior to the Screening Visit must be available to the investigator.
- •?Predominant negative symptoms present for at least 6 months at the Screening Visit, based on the medical records and the judgment of the investigator.
- •?A Positive and Negative Syndrome Scale (PANSS) factor score for negative symptoms > or = 24.
- •?A score of > or = 4 on a minimum 2 of the 3 PANSS items
- •oFlat affect (N1 ? Blunted affect),
- •oPoverty of speech (N6 ? Lack of spontaneity and flow of conversation),
- •oAvolition (N4 ? Passive/apathetic social withdrawal).
- •?Female patients of non-childbearing potential or non-pregnant, not breast-feeding women of childbearing potential, using adequate birth control methods.
- •?If the patients are treated with antipsychotic medications at the Screening Visit, they must receive one or a maximum of 2 different antipsychotic(s). Dose equivalence of the antipsychotic medications must not be higher than 6 mg risperidone equivalent daily if the patient is treated with 1 antipsychotic and 8 mg equivalent risperidone daily if the patient is treated with 2 antipsychotics (Simpson GM et al., 2006). No change in their antipsychotic medication(s) within 30 days before the Screening Visit is allowed. Dosage may be changed, but not the medication(s).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 411
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 9
排除标准
- •?Current DSM-IV-TR?based primary diagnosis of mental retardation or an axis I disorder, other than schizophrenia.
- •?Other psychiatric, neurological, or behavioural disorders that may interfere with the conduct or interpretation of the study.
- •?The condition of the patient is unstable:
- •oHospital admission for, or history of acute exacerbation of schizophrenia within 6 months prior to the Screening Visit, based on the medical records, or during the 4-week Prospective Lead-in Period.
- •oMajor increase in psychiatric care or imprisonment within the last 6 months prior to the Screening Visit, based on the medical record, or during the 4-week Prospective Lead-in Period.
- •oA total PANSS positive factor score >19.
- •oin order to avoid pseudospecificity a score of ?4 on more than 2 of the following PANSS items: P1 ? delusions, P3 ? hallucinatory behaviour, P5 ? grandiosity, P6 ? suspiciousness, G9 ? unusual thought content.
- •?Substance abuse or dependence (other than nicotine or caffeine) within the prior 12 months.
- •?Presence of moderate to severe depressive symptoms, defined by the Calgary Depression Scale for Schizophrenia (CDSS) total score >6.
- •?The patient has clinically relevant parkinsonian symptoms (EPS) as judged by the investigator and/or clinically significant parkinsonian symptoms as evaluated by the sum of the first 8 items on the SAS > 3.
- •?Treatment with antidepressant medications within 3 months prior to the screening visit.
- •?Being at significant risk of suicide defined as, in the 12 months prior to Screening, significant risk of suicide according to the investigator judgment, based upon all available source of information including those collected in the C-SSRS; and/or within the 5 years prior to Screening, more than one life-threatening suicide attempt.
- •?Known or suspected cluster B personality disorders (borderline, antisocial, histrionic and narcissi personality disorders).
- •?Violent behaviour in the 12 months prior to Screening, according to the investigator?s judgment and/or on PSP scale ?Domain d. ? Disturbing and agressive behaviors? scored as ?Marked?, ?Severe? or ?Very severe? at Screening Visit.
- •?Treatment with risperidone within 6 weeks of the Screening Visit.
- •?History of non-response of a psychotic episode to an adequate trial of risperidone treatment.
- •?Single episode of schizophrenia without residual symptoms (DSM-IV TR criteria).
- •?Treatment with clozapine in the 12 months prior to Screening Visit;
- •except episodic use of clozapine at doses ? 100 mg/day for the
- •treatment of sleep disorder.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of SchizophreniaEUCTR2012-005485-36-BGGedeon Richter Plc420
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of SchizophreniaEUCTR2012-005485-36-PLGedeon Richter Plc420
进行中（未招募）
1 期
A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy ofAsacol® (1.2 to 4.8 g/day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents with Mildly-to-Moderately Active Ulcerative Colitis. - CAMP IIMildly-to-Moderately Active Ulcerative Colitis in Children and AdolescentsMedDRA version: 11.0Level: LLTClassification code 10045365Term: <Manually entered code. Term in E.1.1>EUCTR2007-005702-49-PLProcter & Gamble Pharmaceuticals100
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of SchizophreniaPatients with Predominant Negative Symptoms of SchizophreniaMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2012-005485-36-CZGedeon Richter Plc420
已完成
不适用
A clinical trial of a functional food product in Regulating Blood Glucose in Type 2 Diabetic patientsCTRI/2018/02/012081ITC Life Sciences and Technology Center ITC Ltd450